K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This early-stage study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The goal is to find safe doses and see if th…

This study tests an experimental drug called ZN-c3 in people with a hard-to-treat type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 310 adults with a specific tumor mark…

This study tests a new drug called azenosertib against standard chemotherapy in people with ovarian cancer that no longer responds to platinum-based treatments. The trial includes 420 women whose tumors have a specific protein (cyclin E1). The goal is to see if azenosertib can sl…